

**FOR IMMEDIATE RELEASE:**

---

## **MAKO Surgical Corp. Stockholders Approve Previously Announced Potential Additional Equity Funding**

**FT. LAUDERDALE, FL** — (PRIMENEWSWIRE) — January 27, 2009 — MAKO Surgical Corp. (NASDAQ:MAKO), a medical device company focused on marketing its MAKO RIO™ System, a robotic arm interactive orthopedic surgical platform, and its RESTORIS® implants for minimally invasive orthopedic knee procedures known as MAKOplasty®, announced today that it received necessary stockholder approval for the potential future issuance of \$20 million of common stock along with related warrants to three leading healthcare investment firms as contemplated by its private placement on October 31, 2008. Of the stockholders voting at a special meeting held earlier today, approximately 99% voted to approve the potential issuance of the common stock and warrants.

On October 31, 2008, MAKO completed a private placement of common stock and warrants and raised gross proceeds of \$40 million. As part of this prior financing, MAKO is entitled to require certain lead investors to purchase additional shares of common stock in the aggregate amount of \$20 million. In addition to the stockholder approval obtained today, the issuance of the shares and related warrants is conditioned upon the achievement of certain business-related milestones, including MAKO obtaining regulatory clearance of its RIO system which occurred on November 25, 2008. The remaining milestones, which must be met on or before December 31, 2009 for MAKO to be entitled to require the purchase of the additional securities, include the placing of a specified number of RIO systems and completion of a specified number of MAKOplasty procedures. The specific terms of the business-related milestones and the other conditions related to the potential sale of additional equity were previously disclosed by MAKO and are summarized in filings made by MAKO with the Securities and Exchange Commission.

### **About MAKO Surgical Corp.**

MAKO Surgical Corp. is a medical device company that markets both its robotic arm interactive orthopedic surgical platform and its proprietary RESTORIS® implants for minimally invasive orthopedic knee procedures. The MAKO RIO™ System (RIO) is a surgeon-interactive tactile platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee joint for the insertion and alignment of MAKO's resurfacing implants through a minimal incision. The FDA-cleared RIO allows surgeons to provide a precise, consistently reproducible tissue-sparing, bone resurfacing procedure called MAKOplasty® to a large, yet underserved

patient-specific population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than 200 licensed or owned patents and patent applications relating to the areas of computer assisted surgery, haptics, robotics and implants. Additional information can be found at [www.makosurgical.com](http://www.makosurgical.com).

“MAKOplasty®,” “RIO,” “RESTORIS®,” “Tactile Guidance System” and “TGS,” as well as the “MAKO” logo, whether standing alone or in connection with the words “MAKO Surgical Corp.” are trademarks of MAKO Surgical Corp.

**CONTACT:**

Investors:  
MAKO Surgical Corp.  
Susan M. Verde  
954-927-2044 x349  
[sverde@makosurgical.com](mailto:sverde@makosurgical.com)

or

Westwicke Partners  
Mark Klausner  
443-213-0500  
[mark.klausner@westwicke.com](mailto:mark.klausner@westwicke.com)

Source: MAKO Surgical Corp.